akoya biosciences is developing a novel high-parameter tissue analysis platform, at an order of magnitude beyond what is currently possible. our codex (tm) (co-detection by indexing) system enables deep proteomic profiling...all on your existing microscope. if you are a scientist or software engineer interested in revolutionizing the science of imaging, then akoya is the place for you. contact is at info@akoyabio.com.
Company profile
Ticker
AKYA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
475586242
AKYA stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
4 Mar 24
10-K
2023 FY
Annual report
4 Mar 24
8-K
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
4 Mar 24
8-K
Departure of Directors or Certain Officers
10 Jan 24
8-K
Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook
8 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
8 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
6 Sep 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
7 Aug 23
Transcripts
AKYA
Earnings call transcript
2023 Q3
8 Nov 23
AKYA
Earnings call transcript
2023 Q2
7 Aug 23
AKYA
Earnings call transcript
2023 Q1
8 May 23
AKYA
Earnings call transcript
2022 Q4
6 Mar 23
AKYA
Earnings call transcript
2022 Q3
8 Nov 22
AKYA
Earnings call transcript
2022 Q2
9 Aug 22
AKYA
Earnings call transcript
2022 Q1
8 May 22
AKYA
Earnings call transcript
2021 Q4
15 Mar 22
AKYA
Earnings call transcript
2021 Q3
9 Nov 21
AKYA
Earnings call transcript
2021 Q2
11 Aug 21
Latest ownership filings
4
John Frederick Ek
2 Apr 24
4
Frederic Pla
25 Mar 24
4
Niro Ph.D Ramachandran
25 Mar 24
4
Brian McKelligon
25 Mar 24
4
Brian McKelligon
22 Mar 24
4/A
Brian McKelligon
22 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Brian McKelligon
14 Mar 24
4
ROBERT G SHEPLER
14 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 78.93 mm | 78.93 mm | 78.93 mm | 78.93 mm | 78.93 mm | 78.93 mm |
Cash burn (monthly) | 4.91 mm | (no burn) | 4.30 mm | 5.95 mm | 4.58 mm | 4.61 mm |
Cash used (since last report) | 32.71 mm | n/a | 28.66 mm | 39.63 mm | 30.55 mm | 30.72 mm |
Cash remaining | 46.21 mm | n/a | 50.27 mm | 39.29 mm | 48.37 mm | 48.20 mm |
Runway (months of cash) | 9.4 | n/a | 11.7 | 6.6 | 10.6 | 10.5 |
Institutional ownership, Q3 2023
74.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 65 |
Opened positions | 6 |
Closed positions | 17 |
Increased positions | 31 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 69.62 bn |
Total shares | 36.45 mm |
Total puts | 1.40 k |
Total calls | 32.40 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Telegraph Hill Partners III | 15.68 mm | $239.99 mm |
Blue Water Life Science Advisors | 4.70 mm | $21.84 bn |
PSC Capital Partners | 2.72 mm | $0.00 |
Yair Chaim Schindel | 2.50 mm | $13.60 mm |
Polar Capital | 1.58 mm | $7.35 bn |
BLK Blackrock | 1.45 mm | $6.72 bn |
Vanguard | 1.35 mm | $6.28 bn |
Kent Lake Capital | 746.52 k | $3.47 bn |
Board of Trustees of The Leland Stanford Junior University | 620.43 k | $2.89 bn |
Uniplan Investment Counsel | 554.56 k | $2.58 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | John Frederick Ek | Common Stock | Payment of exercise | Dispose F | No | No | 4.56 | 14,272 | 65.08 k | 180,728 |
23 Mar 24 | Frederic Pla | Common Stock | Payment of exercise | Dispose F | No | No | 4.79 | 2,006 | 9.61 k | 101,500 |
23 Mar 24 | Niro Ph.D Ramachandran | Common Stock | Payment of exercise | Dispose F | No | No | 4.79 | 2,006 | 9.61 k | 207,924 |
23 Mar 24 | Brian McKelligon | Common Stock | Payment of exercise | Dispose F | No | No | 4.79 | 7,135 | 34.18 k | 224,733 |
20 Mar 24 | Brian McKelligon | Common Stock | Sell | Dispose S | No | Yes | 4.9657 | 7,500 | 37.24 k | 231,868 |
20 Mar 24 | Brian McKelligon | Common Stock | Option exercise | Acquire M | No | No | 0.303 | 7,500 | 2.27 k | 239,368 |
20 Mar 24 | Brian McKelligon | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.303 | 7,500 | 2.27 k | 290,629 |
News
UBS Maintains Buy on Akoya Biosciences, Raises Price Target to $7.5
5 Mar 24
Canaccord Genuity Reiterates Buy on Akoya Biosciences, Maintains $10 Price Target
5 Mar 24
Akoya Biosciences Sees FY24 Revenue $114M-$118M Vs $117.38M Est.
4 Mar 24
Recap: Akoya Biosciences Q4 Earnings
4 Mar 24
Akoya Biosciences Q4 2023 GAAP EPS $(0.22) Beats $(0.28) Estimate, Sales $26.49M Beat $25.89M Estimate
4 Mar 24